Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Modifications of Azwell's, Fukujin's Business Reconstruction Plan Approved
September 27, 2004
- Japanese Healthcare Q&A (11)
September 27, 2004
- MOSS Institute Aims to Make Comeback via EDC Business
September 27, 2004
- 61.2% of JMHA Hospitals Recorded Deficits in FY2003: Survey
September 27, 2004
- BUSINESS NEWS IN BRIEF
September 27, 2004
- Proper Use of Anti-cancer Drugs with Add'l Indications Called For
September 27, 2004
- Group to Promote Standardized Cancer Therapy Holds 1st Meeting
September 27, 2004
- 60% of Respondents Support Acceptance of Qualified Foreign Nurses: Survey
September 27, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
September 27, 2004
- MEDICAL DEVICE NEWS IN BRIEF
September 27, 2004
- DIAGNOSTIC NEWS IN BRIEF
September 27, 2004
- WORLD NEWS IN BRIEF
September 27, 2004
- GSK to Broadcast Educational Drama on Depression via Web
September 27, 2004
- AdvaMed "Bringing Innovative Med Technology to Patients Worldwide": Mr Collins
September 27, 2004
- Korosho to Request Revision of Package Insert for Iressa
September 27, 2004
- Survey of All Patients Using Remicade Enters 2nd Year: Tanabe
September 27, 2004
- Korosho to Start New Project to Help Development of New Immunosuppression Therapies
September 27, 2004
- Chugai to Drastically Reorganize Marketing System in October
September 27, 2004
- Prefectural Gov'ts Asked to Prepare for Flu Season
September 27, 2004
- Formulation Research Committees of PMAT, OPMA Merge Under Aegis of JPMA
September 27, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…